Shri Banashankari Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.10 M
as on 16-12-2024
- Paid Up Capital ₹ 2.10 M
as on 16-12-2024
- Company Age 10 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -99.79%
(FY 2022)
- Profit 20.37%
(FY 2022)
- Ebitda -11.36%
(FY 2022)
- Net Worth -47.25%
(FY 2022)
- Total Assets -34.56%
(FY 2022)
About Shri Banashankari Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.10 M and a paid-up capital of Rs 2.10 M, as per Ministry of Corporate Affairs (MCA) records.
Satya Kammila, Phani Ramella, and Paidiwar Srinivas serve as directors at the Company.
- CIN/LLPIN
U74900KA2014PTC074302
- Company No.
074302
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Mar 2014
- Date of AGM
27 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Shri Banashankari Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satya Kammila  | Director | 29-Sep-2021 | Current |
| Phani Ramella | Director | 24-Sep-2014 | Current |
| Paidiwar Srinivas | Director | 27-Aug-2019 | Current |
Financial Performance of Shri Banashankari Pharma.
Shri Banashankari Pharma Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 99.79% decrease. The company also saw a substantial improvement in profitability, with a 20.37% increase in profit. The company's net worth observed a substantial decline by a decrease of 47.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shri Banashankari Pharma?
In 2022, Shri Banashankari Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sai Sridhar Pharma Private LimitedActive 17 years 2 monthsSatya Kammila, Phani Ramella and 1 more are mutual person
- Wynclark Pharmaceuticals Private LimitedActive 17 years 10 months
Satya Kammila and Paidiwar Srinivas are mutual person
- Deccan Medisales Private LimitedActive 13 years 6 months
Satya Kammila, Phani Ramella and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Shri Banashankari Pharma?
Unlock and access historical data on people associated with Shri Banashankari Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shri Banashankari Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shri Banashankari Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
